- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
December 27th, 2005
Jack Uldrich: Late last week, Westaim Corp (Nasdaq: WEDX) priced the IPO of 4.5 million shares of its subsidiary, Nucryst Pharmaceuticals (Nasdaq: NCST), at $10 a share -- well below the forecast price of $12 to $14.
Although Nucryst is a legitimate nanotech company and its IPO deserves to be taken seriously, investors should proceed with great caution because they risk getting burned.
|Related News Press|
PEN Inc. Announces 1-for-180 Reverse Stock Split January 27th, 2016
Properties of Polymeric Nanofibers Optimized to Treat Damaged Body Tissues February 12th, 2016
SLAC X-ray laser turns crystal imperfections into better images of important biomolecules: New method could remove major obstacles to studying structures of complex biological machines February 11th, 2016
Russia’s Nano-enabled Products Market to Witness Massive Growth February 8th, 2011
Adept Technology Announces Orders for Over $600K from Chinese Partner January 18th, 2011
Nanostart-held ItN Nanovation Receives Major Follow-on Order in Saudi Arabia November 29th, 2010
Homegrown Companies Developing Batteries for Clean Energy Storage November 2nd, 2010